ArticleEmerging microbes & infections2025
Enhanced variant neutralization through glycan masking of SARS-CoV-2 XBB1.5 RBD.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 continues to evolve antigenically under the immune pressure exerted by both natural infection and vaccination. As new variants emerge, we face the recurring challenge of updating vaccines at significant financial cost to maintain their efficacy. To address this, novel strategies are needed to enhance the breadth of protection offered by vaccines or, at a minimum, extend their effectiveness over time. One such strategy is antigen modification. In this study, we introduce a glycosylation site into a binding but non-neutralizing epitope within the SARS-CoV-2 XBB.1.5 receptor binding domain (RBD) to redirect the immune response towards more potent neutralizing epitopes. Immunization of mice with this modified antigen via the mRNA vaccine platform resulted in a dramatic increase in neutralizing antibodies compared to the wild-type XBB.1.5 RBD, showing superior protection against a range of SARS-CoV-2 Omicron variants, from BA.2 to JN.1. Our findings reinforce the power of the glycan masking approach, which in combination with the now well-established mRNA vaccine platform can contribute to broader and better vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.